Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE1
Total Enrollment
19 participants
Study Classification
INTERVENTIONAL
Study Start Date
2008-09-30
Study Completion Date
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Osteoporosis is one of the most common skeletal disorders. Today in the United States, 10 million individuals have osteoporosis and 34 million more have low bone mass or osteopenia, which places them at an increased risk of some day developing osteoporosis. Of the people affected by this problem, 68% are women.The current thinking on the development of osteoporosis is that the changes in bone turnover that occur with aging play a major factor. Many modalities of treatment are used to prevent the bone loss and increased fracture risk associated with osteoporosis and osteopenia. Melatonin supplementation may be another treatment modality that lowers risk of hip fracture in perimenopausal women. Melatonin can remodel bone in animal models and in culture. Melatonin works through melatonin receptors to form osteoblasts from human mesenchymal stem cells and has been shown to inhibit osteoclast activity in rodents. Melatonin levels have been correlated with modulating bone markers; low nocturnal levels of melatonin correlate with in an increase in bone marker metabolism and osteoporosis. It is been shown that women who have worked night-shifts for greater than 20 years have increased risk for wrist and hip fractures. Night-shift workers have lower nocturnal melatonin levels than people who do not work the night-shift. The addition of exogenous melatonin suppresses bone marker metabolism. In human stem cells taken from bone marrow, melatonin increases the activity of bone-forming cells called osteoblasts. It is hypothesized that melatonin will improve bone health, menopausal quality of life and sleep compared to placebo in perimenopausal women. In particular, the investigators expect perimenopausal women taking melatonin to show an improvement in overall bone health as revealed by a reduction in bone marker turnover since bone resorption increases more so than bone absorption in this population compared to those women taking placebo. We also expect that perimenopausal women taking melatonin to have better control over their menopausal symptoms, better quality of life and less sleep disturbances when compared to their placebo controls since melatonin is known to modulate estrogen levels in the body and regulate sleep. The data from these studies may provide novel and alternative uses for melatonin; in particular its use for the prevention and/or treatment of osteoporosis.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Melatonin and Osteogenic Loading on Osteopenia
NCT04233112
Osteopenia
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
Treatment of Osteopenia With Melatonin
NCT01690000
Osteoporosis
COMPLETED
NA
The Effects of Melatonin Treatment on Bone, Marrow, Sleep and Blood Pressure
NCT04864509
Osteoporosis, Postmenopausal
UNKNOWN
PHASE4
Herbal Teas on Bone Health in an Osteopenic Population
NCT03480126
Osteopenia
COMPLETED
NA
OSTPRE-Fracture Prevention Study
NCT00592917
Fractures
Osteoporosis
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
BACKGROUND AND SIGNIFICANCE Osteoporosis is one of the most common skeletal disorders. Today in the United States, 10 million individuals have osteoporosis and 34 million more have low bone mass or osteopenia, which places them at an increased risk of some day developing osteoporosis. Of the people affected by this problem, 68% are women.\[1\] Osteoporosis is characterized by low bone mass and microarchitectural disruption, such that fewer, thinner bony spicules are present leading to less structural support. These hallmark features of osteoporosis lead to increased skeletal fragility and an increased fracture risk.\[2\] Hip fracture specifically has been shown to be a major problem leading to increased morbidity and mortality.\[3\] In addition osteoporotic fractures are responsible for a large portion of health care spending. In 1995 $13.8 billion in health care expenditures were attributable to osteoporotic fractures.\[4\] Because the health of older adults often deteriorates after hip fracture, efforts to prevent fracture by treating and preventing osteoporosis are critical to reducing this common cause of morbidity, mortality and health service utilization.
The current thinking on the development of osteoporosis is that the changes in bone turnover that occur with aging play a major factor. One study which measured markers of bone formation, such as osteocalcin (OC), and markers of bone resorption, such as type I collagen cross-linked N-telopeptide (NTX), showed that rates of bone formation and resorption are high in elderly women. However, bone resorption increases more so than bone formation leading resorption to be the major determinant of bone mass.\[5\] These biochemical markers of bone formation and resorption may play an important role in monitoring therapy. In a recent review that examined clinical studies in which bone turnover markers were measured after beginning treatment with a bisphosphonate, the data showed that suppression of bone turnover markers occurred after as little as three months of therapy.\[6,7\] This suppression in bone turnover markers was also associated with reduction in risk for fracture.\[6,7\] Although dual X-ray absorptiometry (DXA) is the gold standard for diagnosis of osteoporosis and osteopenia, recent reports are showing that DXA may not be the best method for measuring bone health. For example, bone fractures routinely occur despite modest bone mineral density levels and no significant reduction in the risk of fracture occurs in patients taking one of the two standard medications, one that significantly increases bone mineral density and the other that moderately increases it.\[6\] Thus, it is currently thought that bone quality may not be clinically assessed by measures other than the determination of bone metabolism with biochemical markers of bone turnover because these markers measure "living" bone cells.\[6\] Many modalities of treatment are used to prevent the bone loss and increased fracture risk associated with osteoporosis and osteopenia. One method involves use of calcium and vitamin D supplementation such that total calcium intake is approximately 1500 mg/day. Calcium and vitamin D supplementation may increase bone mineral density to a small extent, but not nearly to the same degree as is seen with other treatment modalities.\[8\] Therefore, it is often combined with another treatment method for better efficacy. Bisphosphonates are being used more and more often in postmenopausal women. These antiresorptive agents have been shown to prevent bone loss and reduce the incidence of vertebral and nonvertebral fractures.\[9\] Calcitonin has been shown to decrease vertebral fractures, increase bone mineral density at the lumbar spine and inhibit bone turnover.\[10\]
Melatonin supplementation may be another treatment modality that lowers risk of hip fracture in perimenopausal women. Melatonin can remodel bone in animal models and in culture.\[11\] Melatonin works through melatonin receptors to form osteoblasts from human mesenchymal stem cells\[12\] and has been shown to inhibit osteoclast activity in rodents.\[13\] Melatonin levels have been correlated with modulating bone markers whereby low nocturnal levels of melatonin correlate with in an increase in bone marker metabolism and osteoporosis.\[14\] The addition of exogenous melatonin suppresses bone marker metabolism.\[15\] Work from my laboratory reveals that application of melatonin to human bone stem cells grown in culture enhances alkaline phosphatase activity by 50% and calcium deposition by 10-fold.\[16\]
HYPOTHESIS AND SPECIFIC AIMS We hypothesize that melatonin will improve bone health, menopausal quality of life and sleep compared to placebo in perimenopausal women.
1. Assess the feasibility of recruiting perimenopausal women willing to be enrolled in a randomized, trial of melatonin versus placebo
2. Assess the effects of melatonin versus placebo on markers of bone health, quality of life, and sleep disturbance.
PRIMARY ENDPOINTS: The primary outcome variables are bone turnover marker status, and melatonin levels as measured in blood and bone density as measured by the Achilles method.
SECONDARY ENDPOINTS:
1. Quality of life as measured by the MenQOL, a validated scale of menopausal quality of life
2. Sleep, as measured by the Pittsburgh Sleep Questionnaire
RESEARCH PLAN This study is a longitudinal, cohort trial of 20 subjects who are perimenopausal and aged 45 years old or greater who have new onset of irregular menses not due to other known causes such as polycystic ovaries or hypothyroidism. Perimenopause is defined as the time between the onset of menstrual irregularity and menopause; there is no lab test that is diagnostic of perimenopause. Thus, the investigators will include women who, according to their age, are likely to be perimenopausal (age 45 or greater) and who have symptoms of perimenopause (irregular menses). Once a cohort of 20 subjects is recruited, the investigators will randomize volunteers using a computer-generated blocked randomization scheme. Five study subjects will receive placebo and 15 study subjects will receive melatonin, 3 mg). The women enrolled in the study will be asked to take their treatments by mouth at bedtime each day for 6 months to coincide with the nocturnal surge in melatonin each day. This dose of melatonin has been chosen because 3 mg melatonin is commonly used to induce phase-shifts in circadian rhythms in people.\[17\] Seeing that this is one of our secondary endpoints, this dose is appropriate. Regarding melatonin's effects on bone, there is nothing known about its efficacy on forming bone in women. Therefore, the dose of melatonin was chosen based on the reported literature using pre-clinical or in vitro culture models that showed positive effects on bone formation. These reports show variable effects of melatonin ranging from 400 pM in rat \[15\], to 5 mg melatonin in mouse (unpublished data) to 50 nM on human mesenchymal stem cells grown in culture.\[12,16\] The bioavailability of melatonin is 17% in females taking 250 mcg melatonin po.\[18\] Thus, a 3 mg dose of melatonin taken by mouth would result in a nocturnal exogenous level of 2.19 mM. The terminal half-life of melatonin is about 41 minutes in females \[18\], however, accumulation of melatonin in the bone marrow occurs \[11\]. Therefore, these data suggest that our 3 mg dose is appropriate for these studies.
PLANS FOR ASSESSMENT AND STUDY OUTCOMES Our primary outcome will be the levels of bone turnover markers, OC and NTX, bone density and melatonin taken at baseline and then after 6 months of treatment. The change in bone turnover marker levels will be compared between those taking melatonin and those taking placebo. Baseline levels of OC and NTX will be calculated. For this study the investigators will also visually inspect the data in order to perform descriptive analyses of the demographic characteristics of our population, such as age, and weight. We will explore characteristics of any individuals who have a significant improvement in their bone turnover markers, such as compliance with the treatment, diet, and lifestyle as determined by the diary. We will also make note of characteristics such as current or past cigarette smoking and alcohol and caffeine consumption as individuals with these risk factors may show less improvement in their bone turnover markers. We will use intention to treat as our primary analysis. We will attempt to minimize missing data with careful follow-up of subjects, maintaining consistent contact with them over the study period, and remunerating them for their inconvenience. If a subject drops out of the study, the investigators will still attempt to obtain their follow up studies.
Expected Outcomes.We expect perimenopausal women taking melatonin to show an improvement in overall bone health as revealed by an increase in bone density, an increase in OC and a decrease in NTX levels when compared to those women taking placebo. We also expect those taking melatonin to have better control over their menopausal symptoms, better quality of life and less sleep disturbances compared to their placebo controls. The potential benefits of participating in this study include the possibility of decreasing bone turnover and reducing fracture risk as well as improve sleep regardless, a condition much affected in this population of women. The data from these studies may provide novel and alternative uses for melatonin for the prevention of osteoporosis and provide women with more options to manage diseases associated with menopause.
The current thinking on the development of osteoporosis is that the changes in bone turnover that occur with aging play a major factor. One study which measured markers of bone formation, such as osteocalcin (OC), and markers of bone resorption, such as type I collagen cross-linked N-telopeptide (NTX), showed that rates of bone formation and resorption are high in elderly women. However, bone resorption increases more so than bone formation leading resorption to be the major determinant of bone mass.\[5\] These biochemical markers of bone formation and resorption may play an important role in monitoring therapy. In a recent review that examined clinical studies in which bone turnover markers were measured after beginning treatment with a bisphosphonate, the data showed that suppression of bone turnover markers occurred after as little as three months of therapy.\[6,7\] This suppression in bone turnover markers was also associated with reduction in risk for fracture.\[6,7\] Although dual X-ray absorptiometry (DXA) is the gold standard for diagnosis of osteoporosis and osteopenia, recent reports are showing that DXA may not be the best method for measuring bone health. For example, bone fractures routinely occur despite modest bone mineral density levels and no significant reduction in the risk of fracture occurs in patients taking one of the two standard medications, one that significantly increases bone mineral density and the other that moderately increases it.\[6\] Thus, it is currently thought that bone quality may not be clinically assessed by measures other than the determination of bone metabolism with biochemical markers of bone turnover because these markers measure "living" bone cells.\[6\] Many modalities of treatment are used to prevent the bone loss and increased fracture risk associated with osteoporosis and osteopenia. One method involves use of calcium and vitamin D supplementation such that total calcium intake is approximately 1500 mg/day. Calcium and vitamin D supplementation may increase bone mineral density to a small extent, but not nearly to the same degree as is seen with other treatment modalities.\[8\] Therefore, it is often combined with another treatment method for better efficacy. Bisphosphonates are being used more and more often in postmenopausal women. These antiresorptive agents have been shown to prevent bone loss and reduce the incidence of vertebral and nonvertebral fractures.\[9\] Calcitonin has been shown to decrease vertebral fractures, increase bone mineral density at the lumbar spine and inhibit bone turnover.\[10\]
Melatonin supplementation may be another treatment modality that lowers risk of hip fracture in perimenopausal women. Melatonin can remodel bone in animal models and in culture.\[11\] Melatonin works through melatonin receptors to form osteoblasts from human mesenchymal stem cells\[12\] and has been shown to inhibit osteoclast activity in rodents.\[13\] Melatonin levels have been correlated with modulating bone markers whereby low nocturnal levels of melatonin correlate with in an increase in bone marker metabolism and osteoporosis.\[14\] The addition of exogenous melatonin suppresses bone marker metabolism.\[15\] Work from my laboratory reveals that application of melatonin to human bone stem cells grown in culture enhances alkaline phosphatase activity by 50% and calcium deposition by 10-fold.\[16\]
HYPOTHESIS AND SPECIFIC AIMS We hypothesize that melatonin will improve bone health, menopausal quality of life and sleep compared to placebo in perimenopausal women.
1. Assess the feasibility of recruiting perimenopausal women willing to be enrolled in a randomized, trial of melatonin versus placebo
2. Assess the effects of melatonin versus placebo on markers of bone health, quality of life, and sleep disturbance.
PRIMARY ENDPOINTS: The primary outcome variables are bone turnover marker status, and melatonin levels as measured in blood and bone density as measured by the Achilles method.
SECONDARY ENDPOINTS:
1. Quality of life as measured by the MenQOL, a validated scale of menopausal quality of life
2. Sleep, as measured by the Pittsburgh Sleep Questionnaire
RESEARCH PLAN This study is a longitudinal, cohort trial of 20 subjects who are perimenopausal and aged 45 years old or greater who have new onset of irregular menses not due to other known causes such as polycystic ovaries or hypothyroidism. Perimenopause is defined as the time between the onset of menstrual irregularity and menopause; there is no lab test that is diagnostic of perimenopause. Thus, the investigators will include women who, according to their age, are likely to be perimenopausal (age 45 or greater) and who have symptoms of perimenopause (irregular menses). Once a cohort of 20 subjects is recruited, the investigators will randomize volunteers using a computer-generated blocked randomization scheme. Five study subjects will receive placebo and 15 study subjects will receive melatonin, 3 mg). The women enrolled in the study will be asked to take their treatments by mouth at bedtime each day for 6 months to coincide with the nocturnal surge in melatonin each day. This dose of melatonin has been chosen because 3 mg melatonin is commonly used to induce phase-shifts in circadian rhythms in people.\[17\] Seeing that this is one of our secondary endpoints, this dose is appropriate. Regarding melatonin's effects on bone, there is nothing known about its efficacy on forming bone in women. Therefore, the dose of melatonin was chosen based on the reported literature using pre-clinical or in vitro culture models that showed positive effects on bone formation. These reports show variable effects of melatonin ranging from 400 pM in rat \[15\], to 5 mg melatonin in mouse (unpublished data) to 50 nM on human mesenchymal stem cells grown in culture.\[12,16\] The bioavailability of melatonin is 17% in females taking 250 mcg melatonin po.\[18\] Thus, a 3 mg dose of melatonin taken by mouth would result in a nocturnal exogenous level of 2.19 mM. The terminal half-life of melatonin is about 41 minutes in females \[18\], however, accumulation of melatonin in the bone marrow occurs \[11\]. Therefore, these data suggest that our 3 mg dose is appropriate for these studies.
PLANS FOR ASSESSMENT AND STUDY OUTCOMES Our primary outcome will be the levels of bone turnover markers, OC and NTX, bone density and melatonin taken at baseline and then after 6 months of treatment. The change in bone turnover marker levels will be compared between those taking melatonin and those taking placebo. Baseline levels of OC and NTX will be calculated. For this study the investigators will also visually inspect the data in order to perform descriptive analyses of the demographic characteristics of our population, such as age, and weight. We will explore characteristics of any individuals who have a significant improvement in their bone turnover markers, such as compliance with the treatment, diet, and lifestyle as determined by the diary. We will also make note of characteristics such as current or past cigarette smoking and alcohol and caffeine consumption as individuals with these risk factors may show less improvement in their bone turnover markers. We will use intention to treat as our primary analysis. We will attempt to minimize missing data with careful follow-up of subjects, maintaining consistent contact with them over the study period, and remunerating them for their inconvenience. If a subject drops out of the study, the investigators will still attempt to obtain their follow up studies.
Expected Outcomes.We expect perimenopausal women taking melatonin to show an improvement in overall bone health as revealed by an increase in bone density, an increase in OC and a decrease in NTX levels when compared to those women taking placebo. We also expect those taking melatonin to have better control over their menopausal symptoms, better quality of life and less sleep disturbances compared to their placebo controls. The potential benefits of participating in this study include the possibility of decreasing bone turnover and reducing fracture risk as well as improve sleep regardless, a condition much affected in this population of women. The data from these studies may provide novel and alternative uses for melatonin for the prevention of osteoporosis and provide women with more options to manage diseases associated with menopause.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Osteoporosis
Osteopenia
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
PREVENTION
Blinding Strategy
TRIPLE
Participants
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sugar pill
Group Type
PLACEBO_COMPARATOR
sugar pill
Intervention Type
DIETARY_SUPPLEMENT
lactose p.o. at bedtime daily
melatonin
Group Type
ACTIVE_COMPARATOR
melatonin
Intervention Type
DIETARY_SUPPLEMENT
3mg p.o. at bedtime daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
melatonin
3mg p.o. at bedtime daily
Intervention Type
DIETARY_SUPPLEMENT
sugar pill
lactose p.o. at bedtime daily
Intervention Type
DIETARY_SUPPLEMENT
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Nature's Bounty Melatonin
Natrol Melatonin
Spring Valley Melatonin
Lactose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* willingness to participate in the 6-month study, willingness to undergo testing of bone turnover markers before and after the drug therapies and willingness to provide a self-assessment on quality of life and sleep throughout the program.
* Subjects must be willing to take their treatments right before bed and to not to consume alcohol with this medication.
* Subjects must be willing to take their treatments right before bed and to not to consume alcohol with this medication.
Exclusion Criteria
* Those individuals on osteoporotic drugs, hypnotics, CYP1A2 inhibiting drugs, fluvoxamine or those with severe sleep apnea, severe COPD and those with moderate or severe hepatic impairment will also be excluded.
* Individuals who are lactose intolerant will also be excluded because the placebo and melatonin capsules will contain lactose.
* Individuals who are lactose intolerant will also be excluded because the placebo and melatonin capsules will contain lactose.
Minimum Eligible Age
45 Years
Maximum Eligible Age
54 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Duquesne University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paula A Witt-Enderby, PhD
Role: PRINCIPAL_INVESTIGATOR
Duquesne University School of Pharmacy
Judith L Balk, MD
Role: PRINCIPAL_INVESTIGATOR
Magee-Womens Hospital, University of Pittsburgh
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Duquesne University School of Pharmacy Center for Pharmacy Care
Pittsburgh, Pennsylvania, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
www.osteo.org. Osteoporosis Overview. National Institute of Health Osteoporosis and Related Bone Disease. June 2005.
Reference Type
BACKGROUND
Parfitt AM, Villanueva AR, Foldes J, Rao DS. Relations between histologic indices of bone formation: implications for the pathogenesis of spinal osteoporosis. J Bone Miner Res. 1995 Mar;10(3):466-73. doi: 10.1002/jbmr.5650100319.
Reference Type
BACKGROUND
Wolinsky FD, Fitzgerald JF, Stump TE. The effect of hip fracture on mortality, hospitalization, and functional status: a prospective study. Am J Public Health. 1997 Mar;87(3):398-403. doi: 10.2105/ajph.87.3.398.
Reference Type
BACKGROUND
Ray NF, Chan JK, Thamer M, Melton LJ 3rd. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997 Jan;12(1):24-35. doi: 10.1359/jbmr.1997.12.1.24.
Reference Type
BACKGROUND
Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996 Mar;11(3):337-49. doi: 10.1002/jbmr.5650110307.
Reference Type
BACKGROUND
Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, Fukunaga M, Hosoi T, Miki T, Chaki O, Ichimura S, Nakatsuka K, Miura M; Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society. Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab. 2005;23(2):97-104. doi: 10.1007/s00774-004-0547-6. No abstract available.
Reference Type
BACKGROUND
Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med. 2006 Apr;119(4 Suppl 1):S25-31. doi: 10.1016/j.amjmed.2005.12.020.
Reference Type
BACKGROUND
Riggs BL, O'Fallon WM, Muhs J, O'Connor MK, Kumar R, Melton LJ 3rd. Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. J Bone Miner Res. 1998 Feb;13(2):168-74. doi: 10.1359/jbmr.1998.13.2.168.
Reference Type
BACKGROUND
Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med. 1998 Feb 19;338(8):485-92. doi: 10.1056/NEJM199802193380801.
Reference Type
BACKGROUND
Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000 Sep;109(4):267-76. doi: 10.1016/s0002-9343(00)00490-3.
Reference Type
BACKGROUND
Witt-Enderby PA, Radio NM, Doctor JS, Davis VL. Therapeutic treatments potentially mediated by melatonin receptors: potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy. J Pineal Res. 2006 Nov;41(4):297-305. doi: 10.1111/j.1600-079X.2006.00369.x.
Reference Type
BACKGROUND
Radio NM, Doctor JS, Witt-Enderby PA. Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade. J Pineal Res. 2006 May;40(4):332-42. doi: 10.1111/j.1600-079X.2006.00318.x.
Reference Type
BACKGROUND
Koyama H, Nakade O, Takada Y, Kaku T, Lau KH. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation. J Bone Miner Res. 2002 Jul;17(7):1219-29. doi: 10.1359/jbmr.2002.17.7.1219.
Reference Type
BACKGROUND
Ostrowska Z, Kos-Kudla B, Marek B, Kajdaniuk D. Influence of lighting conditions on daily rhythm of bone metabolism in rats and possible involvement of melatonin and other hormones in this process. Endocr Regul. 2003 Sep;37(3):163-74.
Reference Type
BACKGROUND
Ostrowska Z, Kos-Kudla B, Nowak M, Swietochowska E, Marek B, Gorski J, Kajdaniuk D, Wolkowska K. The relationship between bone metabolism, melatonin and other hormones in sham-operated and pinealectomized rats. Endocr Regul. 2003 Dec;37(4):211-24.
Reference Type
BACKGROUND
Sethi S, Radio NM, Kotlarczyk MP, Chen CT, Wei YH, Jockers R, Witt-Enderby PA. Determination of the minimal melatonin exposure required to induce osteoblast differentiation from human mesenchymal stem cells and these effects on downstream signaling pathways. J Pineal Res. 2010 Oct;49(3):222-38. doi: 10.1111/j.1600-079X.2010.00784.x. Epub 2010 Jul 6.
Reference Type
BACKGROUND
Burgess HJ, Revell VL, Eastman CI. A three pulse phase response curve to three milligrams of melatonin in humans. J Physiol. 2008 Jan 15;586(2):639-47. doi: 10.1113/jphysiol.2007.143180. Epub 2007 Nov 15.
Reference Type
BACKGROUND
Fourtillan JB, Brisson AM, Gobin P, Ingrand I, Decourt JP, Girault J. Bioavailability of melatonin in humans after day-time administration of D(7) melatonin. Biopharm Drug Dispos. 2000 Jan;21(1):15-22. doi: 10.1002/1099-081x(200001)21:13.0.co;2-h.
Reference Type
BACKGROUND
Kotlarczyk MP, Lassila HC, O'Neil CK, D'Amico F, Enderby LT, Witt-Enderby PA, Balk JL. Melatonin osteoporosis prevention study (MOPS): a randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women. J Pineal Res. 2012 May;52(4):414-26. doi: 10.1111/j.1600-079X.2011.00956.x. Epub 2012 Jan 6.
Reference Type
RESULT
Related Links
Access external resources that provide additional context or updates about the study.
http://www.osteo.org
Osteoporosis Overview. National Institute of Health Osteoporosis and Related Bone Disease. June 2005
http://www.ncbi.nlm.nih.gov/pubmed/22220591
Melatonin Osteoporosis Prevention Study (MOPS): A Randomized, Double-Blind, Placebo-Controlled Study Examining the Effects of Melatonin on Bone Health and Quality of Life in Perimenopausal Women
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07-88
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Investigation of the Effect of BONISTEIN(R) Bone Blend on Bone Mineral Density/Content and Biomarkers of Bone Health
NCT00698984
COMPLETED
NA
Bone Health in Postmenopausal Women: The Effect of Exercise With or Without Medication for Osteoporosis
NCT07267325
NOT_YET_RECRUITING
NA
Osteoporosis Disease Management Demonstration Project (0000-037)
NCT00139425
COMPLETED
NA
Nutritional Supplement and Bone Health in Post-Menopausal Women
NCT03337971
COMPLETED
NA
Effects of Amorphous Calcium Carbonate Supplementation on Bone Health in Postmenopausal Women With Osteopenia
NCT05810909
COMPLETED
NA
Comparison of Osteoporosis Disease Management Strategies (0000-039)
NCT00145080
COMPLETED
NA
Program to Prevent Osteoporosis in Girls
NCT00063024
UNKNOWN
PHASE3
Osteoporosis Prevention in Preadolescent Girls
NCT00000413
COMPLETED
PHASE2
Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
NCT06041789
RECRUITING
PHASE2
Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer
NCT00587925
COMPLETED
NA
Dissemination of a Theory-Based Bone Health Program in Online
NCT01963169
COMPLETED
NA
The Effects of Bovine Colostrum in Bone Metabolism in Humans
NCT04040010
COMPLETED
NA
Strenght Training in Osteoporosis Prevention
NCT06733064
ACTIVE_NOT_RECRUITING
NA
Dried Plums for Bone Health in Older Postmenopausal Women
NCT02325895
COMPLETED
NA
Effectiveness and Safety of EuBone® Capsules for Bone Health in Postmenopausal Women
NCT05402852
UNKNOWN
PHASE4
To Test the Effect of Calcifediol Hy.D Supplementation on Muscle Function and Bone Quality in Younger Postmenopausal Women With Osteopenia
NCT02527668
COMPLETED
PHASE2
Use of Bone Biopsy to Better Understand the Causes of Decreased Bone Mineral Density in Depression
NCT00001916
COMPLETED
Magnesium Supplementation to Prevent Bone Loss
NCT00346658
COMPLETED
PHASE1
A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
NCT01907269
COMPLETED
NA
Moringa Oleifera on Bone Density
NCT03026660
COMPLETED
NA
Preventing Diabetic Osteoporosis With Exercise
NCT03930758
COMPLETED
NA
Prevalence and Predictors of Osteoporosis in the Beijing's Urban Population
NCT01476150
UNKNOWN
Yoga in the Treatment of Osteoporosis
NCT02399176
COMPLETED
NA
Parameters of Exercise to Prevent Osteoporosis
NCT04063813
COMPLETED
NA
Tocotrienols and Bone Health of Postmenopausal Women
NCT02058420
COMPLETED
PHASE1/PHASE2